Repligen Corporation saw its stock price decline steadily and then drop sharply following its February 24 earnings release, according to Brown Capital Management's first-quarter 2026 investor letter. The market reacted poorly to Repligen's initial 2026 financial guidance, which called for 10% to 14% reported revenue growth and 9% to 13% organic growth, signaling a deceleration from the 14% organic growth achieved in the fourth quarter. Brown Capital views the sell-off as an overreaction and still considers Repligen an emerging growth company, citing its differentiated products, expanding portfolio, and exposure to the growing biologics market. Repligen reported first-quarter 2026 revenue of $194 million, a 15% year-over-year increase, and closed at $126.37 per share on June 23, 2026, with a market capitalization of $7.13 billion.
Repligen CorporationInitial 2026 guidance signaled deceleration from Q4 organic growth, causing stock drop.